UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2119-8
Program Prior Authorization/Medical Necessity - Erectile Dysfunction
Medication Stendra® (avanafil)
P&T Approval Date 2/2017, 3/2018, 3/2019, 4/2020, 6/2021, 6/2022, 7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Stendra (avanafil) is a phosphodiesterase 5 inhibitor (PDE5) indicated for the treatment of erectile
dysfunction.
This prior authorization program is intended to encourage the use of lower cost alternatives. This
program requires a member to try two alternative erectile dysfunction medications before providing
coverage for Stendra.
2. Coverage Criteriaa:
A. Stendra will be approved based on ALL of the following criteria:
1. Patient has an organic cause of erectile dysfunction [i.e.: diabetes mellitus, hypertension,
atherosclerosis, drug induced*, hypercholesterolemia, renal insufficiency, neurological
disease (e.g. stroke, seizure disorder, demyelinating disease, spinal cord injury, tumor),
endocrine disorder including hypogonadism, vascular or neurologic disease affecting the
genitalia, or history of male genital surgery (including prostatectomy, trauma, or
irradiation)]
-AND-
2. Patient is not receiving nitrate therapy
-AND-
3. History of failure, contraindication, or intolerance to two of the following (document
drug, date tried and reason for failure):
a. tadalafil (generic Cialis)
b. vardenafil (generic Levitra)
c. sildenafil (generic Viagra)
-AND-
4. Patient is not concurrently receiving an alternative phosphodiesterase-5 enzyme inhibitor
(e.g. Cialis, Levitra, Staxyn, or Viagra).
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services Inc.
1
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
*Examples (not all-inclusive): spironolactone, thiazide diuretics (e.g. chlorthalidone, chlorothiazide,
hydrochlorothiazide), methyldopa, clonidine, guanfacine, reserpine, beta-blockers (e.g. propranolol,
metoprolol), digoxin, tricyclic antidepressants (e.g. amitriptyline, doxepin, imipramine, nortriptyline,
protriptyline), selective serotonin reuptake inhibitors (e.g. citalopram, escitalopram, fluoxetine,
fluvoxamine, paroxetine, sertraline), duloxetine, venlafaxine, cimetidine, phenytoin, carbamazepine,
phenobarbital, primidone, lithium carbonate, chlorpromazine, thioridazine, fluphenazine, trifluoperazine,
finasteride, dutasteride, chronic use of opioids, estrogens, anti-androgens (e.g. bicalutamide, flutamide,
nilutamide), luteinizing hormone releasing hormone agonists (leuprolide, histrelin, goserelin, triptorelin)
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Stendra [package insert]. Freehold, NJ: Metuchen Pharmaceuticals, LLC; November 2022.
2. Drugs That May Cause Male Sexual Dysfunction. Pharmacist’s Letter. Detail Document
#220907. September 2006.
3. Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline. American
Urological Association. 2018.
Program Prior Authorization/Medical Necessity – Stendra
Change Control
Date Change
2/2017 New program.
3/2018 Annual review. Clarified existing criteria with no change to intent and
updated references.
3/2019 Changed the required step agents from brand Cialis to generic tadalafil
and brand Levitra to generic vardenafil. Updated references.
4/2020 Updated references.
6/2021 Annual review. Updated references.
6/2022 Annual review. Updated references.
7/2023 Annual review. Updated references.
7/2024 Annual review. Updated references.
© 2024 UnitedHealthcare Services Inc.
2